Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECT OF RECOMBINANT HUMAN INTERLEUKIN-3 ON HEMATOLOGICAL RECOVERY FROM CHEMOTHERAPY-INDUCED MYELOSUPPRESSION
Autore:
TEPLER I; ELIAS A; KALISH L; SHULMAN L; STRAUSS G; SKARIN A; LYNCH T; LEVITT D; RESTA D; DEMETRI G; GAYNES L; SCHNIPPER L;
Indirizzi:
BETH ISRAEL HOSP,330 BROOKLINE AVE BOSTON MA 02215 DANA FARBER CANC INST BOSTON MA 00000 BRIGHAM & WOMENS HOSP BOSTON MA 00000 HARVARD UNIV,SCH MED,HARVARD COMMUNITY HLTH PLAN BOSTON MA 00000 SANDOZ PHARMACEUT CORP,CYTOKINE DEV UNIT E HANOVER NJ 00000
Titolo Testata:
British Journal of Haematology
fascicolo: 4, volume: 87, anno: 1994,
pagine: 678 - 686
SICI:
0007-1048(1994)87:4<678:EORHIO>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; TRANSITIONAL-CELL-CARCINOMA; BONE-MARROW FAILURE; PHASE-I; PROGENITOR CELLS; GROWTH-FACTORS; GM-CSF; LUNG-CANCER; MACROPHAGE; HEMATOPOIESIS;
Keywords:
INTERLEUKIN 3; IL-3; NSCLC; MYELOSUPPRESSION; PHASE I/II CLINICAL TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
43
Recensione:
Indirizzi per estratti:
Citazione:
I. Tepler et al., "EFFECT OF RECOMBINANT HUMAN INTERLEUKIN-3 ON HEMATOLOGICAL RECOVERY FROM CHEMOTHERAPY-INDUCED MYELOSUPPRESSION", British Journal of Haematology, 87(4), 1994, pp. 678-686

Abstract

Patients with non-small-cell lung cancer (NSCLC) were treated with ICE chemotherapy (ifosfamide 2000 mg/m(2), days 1-3; carboplatin 300 mg/m(2), day 1; etoposide 75 mg/m(2), days 1-3) intravenously (i.v.) during the first 3 d of a maximum of four 28 d treatment cycles. Interleukin-3 (IL-3) was administered in cycles 2 and 4 as a daily subcutaneous(s.c.) injection on days 5-18. Cohorts of three patients were treatedat dosage levels of 0.5, 1.25, 2.5, 5.0, 10.0 and 15.0 mu g/kg/d. At 15.0 mu g/kg/d a 'flu-like' syndrome of myalgias, arthralgias and fatigue was considered dose-limiting. Other toxicities were headache, fever, urticaria, arrhythmia, chills and flushing. Subsequently, nine patients were added to the group receiving 10 mu g/kg/d. 27 patients received IL-3 after their second course of ICE. At 10 and 15 mu g/kg/d, IL-3 in cycle 2 was associated with enhanced haematological recovery. Depth of neutrophil nadir and days of neutropenia (ANC < 0.5 x 10(9)/l) were reduced in 9/13 patients and in 8/11 patients, respectively. No effect was seen on platelet nadir or days of thrombocytopenia. IL-3 was well tolerated up to 10 mu g/kg/d when given as a daily s.c. injection. Results suggest IL-3 as a potential adjunct to chemotherapy, and further studies to explore administration of IL-3 in combination with other cytokines in this setting are warranted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 11:04:36